Articles On Opthea (ASX:OPT)

Growth shares can be powerful wealth builders when they are held for the long term. The key is finding companies with large markets, improving business models, and the potential to become much bigger over time. Not every growth share will d...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on track to end the day lower. At the time of writing, the benchmark index is down 0.4% to 8,589.7 points. Four ASX shares that are falling more than most today are listed below....

A share sale from Superloop Ltd (ASX: SLC) boss Paul Tyler has put the internet services group back in focus on Tuesday. The Superloop share price is down 4.76% to $3.40 at the time of writing, after the company confirmed its Chief Execu...

Share price weakness is not always a bad thing for income investors. When dividend shares fall, their yields can become more attractive, provided the underlying earnings and distributions remain sustainable. With that in mind, here are thre...

• Seneca’s Ben Richards backs alternative assets, data centres and steelmaking coal • DXN, Sheffield, Ktek and Stakk bolt higher in small caps • Icetana lands well placed as smarter surveillance systems gain traction   Stockhead’s end-of-we...

Good Afternoon and welcome to HotCopper Highlights wrapping up Week 23 of the year, I’m Jon Davidson and in this segment we look at the stocks and company announcements generating the most attention this week on Australia’s #1 finance forum...

The new financial year is only a few weeks away. I think that makes this a good time to look for ASX shares that could be best buys before FY27 begins. The three shares in this article have strong long-term opportunities and I think t...

ASX materials stock IperionX Ltd (ASX: IPX) is in focus today after the company announced the results of a Definitive Feasibility Study. The study was focused on its 100% owned Titan rare earths project located in Tennessee, USA. Com...

On Thursday, the S&P/ASX 200 Index (ASX: XJO) had a difficult session and sank into the red.  The benchmark index fell 1.1% to 8,686.1 points. Will the market be able to bounce back from this on Friday and end the week on a high? Her...

In this week’s HotCopper Wire episode, Isaac McIntyre and Jonathon Davidson really dig into several companies in Week 23, including retail stocks, as well as the “rising” Northern Star (ASX:NST), Vysarn (ASX:VYS) and its hunt for water in W...

The S&P/ASX 200 Index (ASX: XJO) is having a tough time on Thursday. In afternoon trade, the benchmark index is down 1.4% to 8,664.1 points. Four ASX shares that are falling more than most today are listed below. Here's why they are t...

It has been a rough session for IperionX Ltd (ASX: IPX) shares on Thursday. The S&P/ASX 300 Index (ASX: XKO) critical minerals stock is sliding even after releasing a major update on its US project. At the time of writing, the Ipe...

A $5,000 investment can go a long way when spread across a handful of quality ASX dividend shares. The key is finding businesses with the cash flows, assets, or market positions to support shareholder returns over time. With that in mind, h...

Investors hit replay as soft GDP print helps power ASX higher Resources march to fresh highs while tech takes a breather Opthea’s nightmare continues as healthcare stays stuck in Groundhog Year   Today was, actually still is, World Repeat...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.6% to 8,778.3 points. Four ASX shares that have failed to follow the market higher today ar...

With more than 600,000 average monthly users on the HotCopper forums, each and every discussion can move markets. That’s why getting in front of those red-hot trends is key for every trader worth their salt. In this daily HotCopper Trends c...

Opthea Ltd (ASX: OPT) shares have returned to trade with an almighty thud on Wednesday. The ASX biotech share resumed trading today after being suspended for more than a year, from March 2025 to June 2026. Unfortunately for its frustrated s...

Racura executive chair Dr Peter Smith acknowledges investor sentiment towards the local biotech sector is not great, given a string of recent trial setbacks. Not to put too fine a point on it, many of Racura Oncology (ASX:RAC) ASX peers hav...

Highlights Invion shares surged after announcing a new wet AMD collaboration with South Korea’s Sangmyung. The partnership aims to explore a photodynamic therapy approach for difficult eye diseases. Broader biotech activity also inclu...

Invion shares surge 40% on the back of an early stage wet aged-related macular degeneration collab Amplia launches a new pancreatic cancer study, while Island tackles Marburg Micro-X lands US airport security screening extension   Cancer...

Phase III trials are a major catalyst for healthcare companies, mark final proving ground before potential regulatory approval and commercialisation Success can make or break a company with several ASX healthcare names now in the high-stak...

A gaggle of drug developers is due to disclose company-making clinical study results this year While late-stage clinical trial victory does not confer commercial success, the results tend to be ‘do or die’ In the main, share valuations don...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Australian biotechs are successfully turning promising science into a scalable, repe...

Following the clinical trial setbacks from drug developers Opthea, Immutep, Percheron and Argenica Therapeutics, the local sector could really do with a win. Actinogen Medical (ASX:ACW) could be the one to pull the sector out of its funk –...

In the face of a new war crisis weighing heavily on both equities and economics alike, value hunters (both long- and short-term minded alike) are chasing down new targets for 2026. Listen to the HotCopper podcast for in-depth discussion...

Highlights • ASX-listed biotech plunges following significant company update.• Clinical and funding uncertainty weighs on investor sentiment.• Broader healthcare segment reflects volatility across All Ordinaries. An ASX-listed biotech...

With the sun setting on another ‘issues rich’ year for ASX biotechs, Dr Boreham applies his stethoscope to the soaring highlights and cratering lowlights.   As usual we adopt the user-friendly A to Z format. If only drug, device and diagnos...

Opthea opts to pursue a rare lung disease known as LAM ECS Botanics prepares for a whiff of change for US cannabis laws federally Island Pharma strikes a key agreement to carry out US primate trial   Opthea (ASX:OPT) expects its shares to...

AI is assisting in trial design aspects such as patient selection and site location Argenica used UK group Brainomix to get its stroke trial program back on track Listed minnow Pathkey AI crunches 1500 factors that can determine a trial’s...

Two dozen esteemed sector figures recently gathered over lunch to recount their career highs and lows One luminary recalls an uncomfortable close encounter with a drug cartel, while others overcame the impact of academic and corporate frau...

Investors are stumping up cash for life sciences capital raisings – but the stories need to be well presented After an “incredibly tumultuous” nine months, fundraisings are on track to meet last year’s bumper tally of $2.9 billion Two medt...

Highlights Uranium and mining stocks show notable short interest shifts. Industrial and education sectors experience renewed investor attention. ASX 200 stocks reflect broader market sentiment trends. This article expl...

Having satisfied the FDA about safety concerns, Neurizon will motor on to the Healey trial platform LTR Pharma invests $1 million in omega-3 side venture Thanks to options, 4D Medical cashes up   Neurizon Therapeutics (ASX:NUZ) is free to...

Pfizer has become the first Big Pharma company to sign a pricing deal with the Trump administration Bioxyne has the dope on likely US medical pot reforms Paradigm trial gets a knees-up with its first patient dosed The Trump administration...

This month’s savage reaction to Argenica Therapeutics’ (ASX:AGN) stroke drug trial results shows that investors didn’t buy management’s line that the data was “really, really positive – not just on safety, but the efficacy signals”. Argenic...

CSL shares have taken another 8% bath, even though brokers maintain valuations well above the current level Aroa Biosurgery says growing non-US sales should offset the impact of Trumpian tariffs “Opthea 2.0” is likely to stick with its kni...

Highlights Short interest sees notable shifts across energy, resources, and technology stocks Silex Systems experiences heightened attention following capital raise Liontown Resources and others show declining short positions despite...

  Highlights Boss Energy (ASX:BOE), Paladin Energy (ASX:PDN), and Pilbara Minerals (ASX:PLS) remain among the most shorted names Rising short activity observed in Silex Systems (ASX:SLX), Beach Energy (ASX:BPT), and Iluka Resour...

CSL shares tumble 12% on the back of a multi-pronged transformation drive and a perceived weak result The company is paring 3000 jobs in a bid to save up to US$550 million of annualised costs Opthea lives on!   CSL (ASX:CSL) has unveiled...

Eye drug developer Opthea’s cash balance has more than halved as the company wraps up its failed trials Poynovo shares gain 10% after a cracker full-year result Microx leads today’s sector gains after a US deal with a mystery party    The...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Auguring well for upcoming interim results, Regal Partners has provided a positive q...

• Clarity Pharmaceuticals rocket up to 12% after its blitzkrieg placement • Artrya, Botanix and Imricor are among today’s quarterly updates • Lumos outlines US market potential   Radiopharmaceutical group Clarity Pharmaceuticals (ASX:CU6) h...

On Friday the 13th of December last year, Percheron Therapeutics (ASX:PER)  CEO Dr James Garner awaited the top-line results of the phase IIb Duchenne muscular dystrophy trial from his Brisbane lounge room. The company’s clinical developmen...

With the FDA’s blessing, Dimerix will use phase III trial endpoints that could lead to accelerated approval for its kidney disease drug Dimerix is confident of phase III success because an expert ‘peek’ at the blinded data shows it’s on th...

Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector’s best EOFY performer has come from left field: the local and Europ...

Highlights BVF Partners exits Syntara citing fund size constraints, not program performance Trial data for myelofibrosis drug candidate shows continued progress Syntara to discuss future clinical development path with US FDA...

Arovella is one of only a handful of biotechs pursuing CAR-iNKT immunotherapies – and is the only ASX-listed exemplar The “soldiers of the blood stream”, CAR-iNKT cells offer potential advantages including easier off-the-shelf therapies Th...

As a former bus driver, Dimerix (ASX:DXB) CEO Dr Nina Webster knows that the drug development journey is just as important as the destination when it comes to delivering value to shareholders. The therapeutic trip can be painfully long, esp...

Many life science companies stress the virtue of diversity: multiple programs to protect against one of them failing. Diversity can be helpful: after its failed phase III eye disease programs, Opthea would be wishing it had another drug can...

Life science companies are turning to federal research & development tax refund advances to stave off capital raisings on unfavourable terms Biotechs undergoing eligible R&D know they will receive a federal R&D rebate, but ther...